Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
Go back to Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference| (NASDAQ: EDIT) | Delayed: 2.84 +0.04 (1.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.80 | 52 Week High | $43.99 | |||
| Open | $2.72 | 52 Week Low | $12.43 | |||
| Day High | $2.91 | P/E | N/A | |||
| Day Low | $2.72 | EPS | $0.00 | |||
| Volume | 440,074 | |||||
